Analyst Price Target is $54.89
▲ +101.50% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Sensei Biotherapeutics in the last 3 months. The average price target is $54.89, with a high forecast of $60.00 and a low forecast of $50.00. The average price target represents a 101.50% upside from the last price of $27.24.
Current Consensus is
Moderate Buy
The current consensus among 11 contributing investment analysts is to moderate buy stock in Sensei Biotherapeutics. This rating has held steady since June 2026, when it changed from a Hold consensus rating.
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More
